The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...

The rise of weight loss drugs such as Ozempic and Wegovy has changed the way Americans eat and shop, along with how major ...

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.